Immunogenicity and safety of a booster dose of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) compared with HepB-Eng (Engerix-B®) and HepB-AS04 (Fendrix®) in adults receiving hemodialysis who previously received hepatitis B vaccination and are not seroprotected: Results of a randomized, multicenter phase 3 study

• Main Authors: Matthias Girndt (Author), Manfred Plüer (Author), Frank Dellanna (Author), Ann K. Michelsen (Author), Joachim Beige (Author), Kai Toussaint (Author), Hubert J. Wehweck (Author), Michael Koch (Author), Syrus Hafezi Rachti (Author), Justus Faust (Author), Hans-Peter Bosselmann (Author), Oliver Witzke (Author), Robert S. Janssen (Author), the HBV-18 Study Investigators (Author)
• Format: Book
• Published: Taylor & Francis Group, 2022-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

This study compared the immunogenicity and safety of a booster dose of HepB-CpG (HEPLISAV-B® vaccine) with HepB-Eng (Engerix-B®) and HepB-AS04 (Fendrix®) in patients receiving chronic hemodialysis. This was a multicenter, randomized, open-label, phase 3 study of adults receiving hemodialysis with an...